Mandate

Vinge advises the Second Swedish National Pension Fund and the Sixth Swedish National Pension Fund and their portfolio company Norrporten AB (publ) in relation to an exit process

April 15, 2016

Vinge advises the Second Swedish National Pension Fund and the Sixth Swedish National Pension Fund and their portfolio company Norrporten AB (publ) in relation to the exit process entailing a sale of Norrporten to a private buyer or an IPO and listing of shares in Norrporten on Nasdaq Stockholm.

The exit process resulted in a sale of Norrporten to Castellum AB (publ), listed on Nasdaq Stockholm, at a price of SEK 14.0 billion, based on an issue price in Castellum’s issue in kind of SEK 133 per share and including a dividend of SEK 464 million. Castellum will at closing pay SEK 10.4 billion in cash and 23.41 million Castellum shares to the AP-funds. Prior to the sale, Norrporten had been approved for listing on Nasdaq Stockholm by Nasdaq Stockholm’s listing committee.
 
Norrporten is one of Sweden’s largest office property companies with centrally located properties in Swedish urban growth centres and in Copenhagen. As of 31 December 2015, Norrporten’s property portfolio across eleven geographical market areas comprised 120 properties with a total leasable area of more than 1,140,000 square metres and an aggregate property value of SEK 25.8 billion.
 
Vinge’s team primarily consisted of Charlotte Levin, Fredrik Sonander, Joakim Hagberg, Erik Claesson, Nils Fredrik Dehlin and Joel Wahlberg. Maria Schultzberg, Emilie Parland, Ulf Käll and Victor Ericsson assisted in tax related matters, Albert Wållgren and Linn Adelwald assisted in financing related matters, Anna Palmérus and Karin Wisénius in competition law related matters and Åsa Gotthardsson assisted in employment law related matters.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025